

12-20-01

NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)

Duplicate
(check, if applicable)

12/17/01
j1132 U.S. PTO
Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Attorney Docket No. 054474-5005
First Named Inventor: Ettenson
Express Mail Label No. EL231896305US
Total Pages of Transmittal Form: 2

12/17/01
j1132 U.S. PTO
10/02254

Transmitted herewith for filing is the non-provisional utility patent application entitled:

**COMPOSITIONS, METHODS AND KITS RELATING TO THROMBIN DEGRADATION
RESISTANT FIBROBLAST GROWTH FACTOR-1**

which is:

an Original; or
a Continuation, Divisional, or Continuation-in-part (CIP)
of prior Application No. _____ filed _____.
Anticipated Group/Art Unit: _____ or Class _____, Subclass _____.
 This non-provisional patent application is based on Provisional Patent Application
No. _____, filed _____.

Enclosed are:

Specification (including Abstract) and claims: 85 pages.
 Application Data Sheet.
 Newly executed/**unexecuted** Declaration (original/copy).
 Copy of Declaration from prior application.
 Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
 11 Sheets of drawings (formal) plus one copy.
 Microfiche computer program (Appendix).
 Nucleotide and/or Amino Acid Sequence Submission, including:
 Computer readable copy Paper Copy Verified Statement.
 Under PTO-1595 Cover Sheet, an assignment of the invention
 Name of Assignees: Maine Medical Center Research Institute and Repair, Inc.
 Certified copy(ies) of _____ Application No(s). _____ filed _____ is/are filed:
 herewith or in prior application &@.
 Applicant(s), by its/their undersigned attorney, claim(s) Small Entity Status under 37
C.F.R. §1.27 as an Independent Inventor, or a Small Business Concern, or a
Non-Profit Organization.
 Preliminary Amendment.
 Information Disclosure Statement, PTO-1449, and cited references.
 Request for Nonpublication of Application Under 35 U.S.C. §122(b)
 Other:

The filing fee is calculated as follows:

			SMALL ENTITY		LARGE ENTITY		
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE: \$370		BASIC FEE: \$740		
Total	48-20 =	28	X9	\$ 252	OR	X18	\$
Independent	23 -3=	20	X42	\$ 840	OR	X84	\$
[] Multiple Dependent Claims Present			\$140	\$	OR	\$280	\$
			TOTAL	\$ 1,462.00	OR	TOTAL	\$

[] The Commissioner is not authorized to charge the filing fee at this time as we elect to defer payment of the entire filing fee until receipt of a Notice to File Missing Parts.

[X] A check in the amount of \$1,462.00 to cover the filing fee is enclosed.

[X] The Commissioner is hereby authorized to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 054474-5005)** as noted below. A duplicate copy of this sheet is enclosed.

[X] Any overpayments or deficiencies in the above-calculated fee.

[] Filing fee in the amount of \$ _____ as calculated above.

[X] Any additional fees required under 37 C.F.R. § 1.16 and § 1.17.

[X] In the event that a Petition for Extension of Time is required during the prosecution of this application, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account noted above.

CORRESPONDENCE ADDRESS:

December 17, 2001
(Date)

By:

Raquel M. Alvarez
RAQUEL M. ALVAREZ, PH.D., J.D.
Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, L.L.P.
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: 215-963-5000
Direct Dial: 215-963-5403
Facsimile: 215-963-5299
E-Mail: ralvarez@morganlewis.com

[X] Customer Number or Bar Code Label: **028977**

RMA/JAI/prw
Enclosures

NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)

Duplicate
(check, if applicable)

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Attorney Docket No. 054474-5005
First Named Inventor: Ettenson
Express Mail Label No. EL231896305US
Total Pages of Transmittal Form: 2

Transmitted herewith for filing is the non-provisional utility patent application entitled:

**COMPOSITIONS, METHODS AND KITS RELATING TO THROMBIN DEGRADATION
RESISTANT FIBROBLAST GROWTH FACTOR-1**

which is:

an Original; or
a Continuation, Divisional, or Continuation-in-part (CIP)
of prior Application No. _____ filed _____.
Anticipated Group/Art Unit: _____ or Class _____, Subclass _____.
 This non-provisional patent application is based on Provisional Patent Application
No. _____, filed _____.

Enclosed are:

Specification (including Abstract) and claims: 85 pages.
 Application Data Sheet.
 Newly executed/**unexecuted** Declaration (original/copy).
 Copy of Declaration from prior application.
 Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
 11 Sheets of drawings (formal) plus one copy.
 Microfiche computer program (Appendix).
 Nucleotide and/or Amino Acid Sequence Submission, including:
 Computer readable copy Paper Copy Verified Statement.
 Under PTO-1595 Cover Sheet, an assignment of the invention
 Name of Assignees: Maine Medical Center Research Institute and Repair, Inc.
 Certified copy(ies) of _____ Application No(s). _____ filed _____ is/are filed:
 herewith or in prior application &@.
 Applicant(s), by its/their undersigned attorney, claim(s) Small Entity Status under 37
 C.F.R. §1.27 as an Independent Inventor, or a Small Business Concern, or a
 Non-Profit Organization.
 Preliminary Amendment.
 Information Disclosure Statement, PTO-1449, and cited references.
 Request for Nonpublication of Application Under 35 U.S.C. §122(b)
 Other:

The filing fee is calculated as follows:

			SMALL ENTITY		LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE: \$370		BASIC FEE: \$740	
Total	48-20 =	28	X9	\$ 252	OR	X18 \$
Independent	23 -3=	20	X42	\$ 840	OR	X84 \$
[] Multiple Dependent Claims Present			\$140	\$	OR	\$280 \$
			TOTAL	\$ 1,462.00	OR	TOTAL \$

[] The Commissioner is not authorized to charge the filing fee at this time as we elect to defer payment of the entire filing fee until receipt of a Notice to File Missing Parts.

[X] A check in the amount of \$1,462.00 to cover the filing fee is enclosed.

[X] The Commissioner is hereby authorized to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 054474-5005)** as noted below. A duplicate copy of this sheet is enclosed.

[X] Any overpayments or deficiencies in the above-calculated fee.

[] Filing fee in the amount of \$ _____ as calculated above.

[X] Any additional fees required under 37 C.F.R. § 1.16 and § 1.17.

[X] In the event that a Petition for Extension of Time is required during the prosecution of this application, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account noted above.

CORRESPONDENCE ADDRESS:

December 17, 2001
(Date)

By:

Raquel M. Alvarez
RAQUEL M. ALVAREZ, PH.D., J.D.
Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, L.L.P.
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: 215-963-5000
Direct Dial: 215-963-5403
Facsimile: 215-963-5299
E-Mail: ralvarez@morganlewis.com

[X] Customer Number or Bar Code Label: 028977

RMA/JAI/prw
Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of Ettenson, <i>et al.</i>	:	Group Art Unit: NOT YET ASSIGNED
Appln. No:	NOT YET ASSIGNED	:	Examiner: NOT YET ASSIGNED
Filed:	HEREWITH	:	
Title:	COMPOSITIONS, METHODS AND KITS RELATING TO THROMBIN DEGRADATION RESISTANT FIBROBLAST GROWTH FACTOR-1	:	Attorney Docket No. 054474-5005

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

(X) I hereby state, in accordance with the requirements of **37 C.F.R. §1.821(f)**, that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 C.F.R. §1.821(c)** and **(e)**, respectively are the same.

() I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(g)** does not include new matter.

() I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.

() I hereby state that the amendments, made in accordance with **37 C.F.R. §1.825(a)**, included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at Figure 10. I hereby state that the substitute sheets(s) of the Sequence Listing do not include new matter.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(b)**, is the same as the amended Sequence Listing.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

ETTENSON, et al.

December 17, 2001
(Date)

By: Raquel M. Alvarez
RAQUEL M. ALVAREZ, PH.D., J.D.
Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, L.L.P.
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: 215-963-5000
Direct Dial: 215-963-5403
Facsimile: 215-963-5299
E-Mail: ralvarez@morganlewis.com

Enclosures

100 200 300 400 500 600 700 800 900 1000